Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Balaji Amines's revenue for the
three
months ended in Mar. 2026 was ₹3,948 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹14,250 Mil.
Balaji Amines's Revenue per Share for the
three
months ended in Mar. 2026 was ₹124.85.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ₹440.64.
Warning Sign:
Balaji Amines Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Balaji Amines was 1.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -15.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -4.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 10.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Balaji Amines's highest 3-Year average Revenue per Share Growth Rate was 35.60% per year. The lowest was -15.60% per year. And the median was 13.60% per year.
Balaji Amines (NSE:BALAMINES) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Balaji Amines Revenue Related Terms
Balaji Amines Revenue Historical Data
* Premium members only.
The historical data trend for Balaji Amines's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BALAMINES vs LIN, SHW, ECL: Revenue Comparison
For the Specialty Chemicals subindustry, Balaji Amines's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Balaji Amines Revenue vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Balaji Amines's Revenue distribution charts can be found below:
* The bar in red indicates where Balaji Amines's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹14,250 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Balaji Amines (NSE:BALAMINES) has a Revenue of ₹14,250 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Balaji Amines and its competitors.
Is Balaji Amines' Revenue too high?
Balaji Amines' current Revenue is ₹14,250 Mil. Overall, Balaji Amines has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Balaji Amines' Revenue compare to LIN and SHW?
Balaji Amines' Revenue of ₹14,250 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Chemicals company?
A good Revenue depends on the Chemicals industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Balaji Amines and its competitors. Balaji Amines's current Revenue is ₹14,250 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Balaji Amines stock overvalued right now?
Based on GuruFocus' analysis, Balaji Amines (NSE:BALAMINES) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,664.36, compared to a current price of ₹2,371.80 — trading 42.5% above its estimated fair value. The current Revenue is ₹14,250 Mil. Balaji Amines' overall GF Score™ is 78/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Balaji Amines (NSE:BALAMINES), the current Revenue is ₹14,250 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Balaji Amines (NSE:BALAMINES) Overvalued in 2026?
Based on GuruFocus' analysis, Balaji Amines stock appears to be overvalued.
The current stock price of ₹2,371.80 is trading 42.5% above its estimated GF Value™ of ₹1,664.36.
GuruFocus considers Balaji Amines to be Significantly Overvalued.
Key valuation signals for NSE:BALAMINES:
Revenue: ₹14,250 Mil
GF Value™: ₹1,664.36 vs. price of ₹2,371.80 (42.5% above fair value)
No single metric tells the full story. See the NSE:BALAMINES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Balaji Amines Ltd is engaged in the manufacture and sale of aliphatic amines, speciality chemicals, and their derivatives. The Company's manufacturing facilities operate through Distributed Control Systems (DCS), indigenous process technologies, and a Zero Liquid Discharge (ZLD) framework. The business operates through the Chemicals and Hotel segments, with the Chemicals segment generating maximum revenue. Its products include amines such as Mono Methyl Amine (MMA), Di-Methyl Amine (DMA) and others; speciality chemicals such as Morpholine, Acetonitrile (ACN), and others; and amine derivatives such as Mono-Methyl Amine Hydrochloride (MMA HCL), Di-Methyl Amine Hydrochloride (DMA HCL) and others. Geographically, the Company generates maximum revenue from India.
78GF Score
Get the complete analysis for NSE:BALAMINES
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BALAMINES has been successfully added to your 
